Overview:

The management of advanced melanoma continues to evolve rapidly, with oncolytic immunotherapies emerging as pivotal, tailored treatment options. Despite these advancements, challenges with integrating these therapies into multidisciplinary clinical practice remain at the forefront. 

This live, virtual symposium will bring together an expert in the management of melanoma with a local community oncologist to discuss the importance of multidiciplinary collaborative care, and will feature real-world, practical case-based discussions to optimize treatment sequencing and selection in the care of patients with advanced melanoma. A focus on understanding resistance to first-line therapies and exploring advanced therapeutic strategies, such as oncolytic viruses and combination immunotherapies, will help praciticing clinicians navigate the complexities of advanced melanoma treatment. The interactive case-based discussions will provide participants with actionable strategies for lesion prioritization and evaluation, prcedural workflow integration, and insight into evidence-based decision-making to help inform treatment selection. By incorporating the latest clinical trial data, the program will offer insights into the efficacy, safety, and real-world application of these innovative therapies to advance personalized care and optimize outcomes for patients with advanced melanoma.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Evaluate clinical and safety data for second-line therapies in melanoma, including oncolytic viruses, tumor-infiltrating lymphocytes (TILs), and combination immunotherapies, in patients with progression on PD-1 inhibitors.
• Describe the mechanistic rationale, administration techniques, and clinical benefits of oncolytic viruses in advanced melanoma.
• Apply best practices for multidisciplinary care of patients receiving intratumoral oncolytic immunotherapies, including coordination between medical oncologists, interventional radiologists, nurse practitioners, nurses, pharmacists, and surgical oncologists.

Target Audience:

Accreditation/Credit Designation:

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hour. 

Acknowledgment of Educational Support

Have a question for the PER® team?

Email: info@gotoper.com